Merck to Buy Terns for $6.7B to Grow in Blood Cancers
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Merck agreed to buy Terns Pharmaceuticals for $6.7 billion, giving the multinational company access to a promising new leukemia treatment as it faces the patent expiration of its bestselling cancer drug.
_1368066_640x360_2493658179706-640x360.webp&w=3840&q=75)
_1368063_640x360_2493658179709-640x360.webp&w=3840&q=75)

_1368049_640x360_2493677635915-640x360.webp&w=3840&q=75)

_1368024_640x360_2493664323561-640x360.webp&w=3840&q=75)
_1368009_640x360_2493655619666-640x360.webp&w=3840&q=75)
_1368001_640x360_2493655107709-640x360.webp&w=3840&q=75)

_1367862_640x360_2493622339808-640x360.webp&w=3840&q=75)
_1367890_640x360_2493638211745-640x360.webp&w=3840&q=75)
_1367774_640x360_2493568579684-640x360.webp&w=3840&q=75)